Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1144
Shown on this page
12
Current sort
Recently updated
Campus scope
NYU Langone Health, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within NYU Langone Health, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1009–1020 of 1,144 matching trials with a site at NYU Langone Health, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer

NCT03400215
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Diagnostic Breast Cancer Scan, Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 99 Years · Female only
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Recruiting No phase listed Observational

JUPITER 4.0 - Risk Factors for Failure of Isolated Medial Patellofemoral Ligament Reconstruction

NCT06883396
Status at this site: Recruiting
View directory record Official record
Conditions
Patellar Dislocation, Recurrent, Patellar Dislocation, Patellar Instability, Patellofemoral Dislocation, Patellofemoral Joint Dislocation, Patellofemoral Disorder
Interventions
Medial Patellofemoral Ligament (MPFL) Reconstruction
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
10 Years to 35 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Redwood City, California • Gainesville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Recruiting Not applicable Interventional

REFLECT Scoliosis System Post Approval Study

NCT06298812
Status at this site: Enrolling by invitation
View directory record Official record
Conditions
Idiopathic Scoliosis
Interventions
REFLECT Scoliosis Correction System
Device
Lead sponsor
Globus Medical Inc
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Active, not recruiting Phase 2 Interventional

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Interventions
RP1, nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Recruiting Phase 1 Interventional

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

NCT06778863
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
Interventions
CLSP-1025
Drug
Lead sponsor
Clasp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Not yet recruiting Not applicable Interventional

A Social Network Approach to Improve HIV Prevention and Substance Use Treatment For People Who Use Drugs

NCT07409350
Site status not listed — check the official record
View directory record Official record
Conditions
Substance Use, HIV Prevention
Interventions
LINKED, Group Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

NCT04041310
Site status not listed — check the official record
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®
Biological · Drug
Lead sponsor
Nouscom SRL
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Recruiting Phase 3 Interventional

A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

NCT04378790
Status at this site: Recruiting
View directory record Official record
Conditions
Amblyopia
Interventions
Patching, Glasses
Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 13 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
68
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Recruiting Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic HER2-positive Breast Cancer
Interventions
Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Not yet recruiting Not applicable Interventional

Telerehabilitation for Shoulder Surgery Recovery

NCT07392502
Site status not listed — check the official record
View directory record Official record
Conditions
Rotator Cuff Injuries
Interventions
Band Connect, Physical Therapy
Device · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Recruiting Not applicable Interventional

Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease

NCT06071429
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Limb-Threatening Ischemia
Interventions
MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold, Percutaneous Transluminal Angioplasty (PTA)
Device
Lead sponsor
R3 Vascular Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
New York, New York • Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 9, 2026, 4:07 PM EST
Active, not recruiting Not applicable Interventional

Split Chest Breast Neurotization

NCT05757778
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Implant; Complications
Interventions
Sensory Nerve Coaptation
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 9, 2026, 4:07 PM EST

About this NYU Langone Health institution page

What this page lists
ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.